<![CDATA[Novel Macrocyclic EGFR TKI Shows Responses in EGFR C797S–Positive NSCLC]]>

Phase 2positiveBH-30643Positive

AI Analysis

Summary

The OMNI-EGFR inhibitor BH-30643 demonstrated a 45% objective response rate in patients with EGFR C797S-positive NSCLC in the phase 1/2 SOLARA trial. This positive early-stage data supports further development of the macrocyclic EGFR tyrosine kinase inhibitor.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

45% objective response rate in EGFR C797S-positive NSCLC patients

Importance:6/10

Sentiment:

0.75

EGFRNSCLCTKIC797S mutationmacrocyclic inhibitorSOLARA trial

Related Companies

$INTI

Read the original article

Published by Cancer Network on September 16, 2026 2:30 PM

Read Original